




RealRate

PHARMACEUTICAL 2022

RELMADA THERAPEUTICS INC.
Rank 333 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

RELMADA THERAPEUTICS INC. Rank 333 of 475

The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 174% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Net Income, reducing the Economic Capital Ratio by 180% points.

The company's Economic Capital Ratio, given in the ranking table, is -236%, being 40% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	223,298
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,061
Liabilities, Non-Current	0
Other Assets	28
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-48
Property and Equipment	0
Research and Development	90,622
Revenues	0
Selling, General and Administrative Expense	35,082

Output Variable	Value in 1000 USD
Assets	223,326
Liabilities	15,061
Expenses	125,703
Stockholders Equity	208,265
Net Income	-125,752
Comprehensive Net Income	-125,752
Economic Capital Ratio	-236%

